DINVAS-F contains Atorvastatin 10 mg + Fenofibrate 160 mg, offering complementary LDL- and triglyceride-lowering activity for appropriate patients with mixed dyslipidaemia. A differentiated PCD Cardiac-Diabetic portfolio offering.
Selected mixed dyslipidaemia.
Yes.
Both agents can contribute to muscle-related adverse effects.
Use only under physician supervision. Monitor lipid profile and hepatic/clinical parameters as advised.
Muscle pain, nausea, abdominal discomfort and liver enzyme elevations; muscle-related adverse effects require attention with combination therapy.
DINVAS-F: Atorvastatin primarily lowers LDL cholesterol, while Fenofibrate improves triglyceride metabolism and can help increase HDL levels.
